Ibex wins CE mark for AI-powered gastric cancer detection tech

Ibex Medical Analytics announced today that it received CE mark approval for its Galen gastric cancer detection solution.

Tel Aviv, Israel-based Ibex uses artificial intelligence (AI) and machine learning technology to power its Galen platform for cancer diagnostics based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology. Galen won CE mark for detecting breast cancer in 2021.

Ibex designed the first-of-its-kind solution as part of the Galen suite to implement AI for the diagnosis of gastric biopsies. The integrated diagnostic solution supports pathologists in the detection of gastric cancer, H. pylori and other important clinical findings while enabling shorter turnaround times and optimized diagnostic workflows.

CE mark approval comes on the heels of results from a blinded, multi-site clinical study at Medipath in France and Maccabi Healthcare Services in Israel in which Galen Gastric demonstrated high accura…

Read more
  • 0

Ibex appoints new CMO, moves CEO to Boston to lead U.S. expansion

Ibex Medical Analytics announced today that it appointed Dr. Douglas Clark as its new chief medical officer.

In addition to appointing Clark to its executive team, Ibex announced that co-founder & CEO Joseph Mossel will relocate to the U.S. to lead the company’s North American expansion efforts from its Boston headquarters.

Clark previously served as CMO at TriCore, having recorded tenures as a physician, professor of pathology and senior executive across his career. He was the chair of the department of pathology at the University of New Mexico School of Medicine and a professor of pathology and oncology at The Johns Hopkins Medical Institutions.

“I am very excited to join the Ibex team and work closely with physicians and providers as they enhance the quality of cancer diagnosis with Ibex’s strong AI,” Clark said in a news release. “My entire career has been dedicated to driving innovation in the pathology laboratory a…

Read more
  • 0

Ibex AI-enabled breast cancer diagnostic lands CE mark

Ibex Medical Analytics announced today that it received CE mark approval for its Galen AI-based breast cancer diagnostic platform.

Tel Aviv-based Ibex’s Galen platform uses AI and machine learning technology based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology, according to a news release.

Galen previously won CE mark approval as a software platform for identifying suspected cancer on prostate core needle biopsies. Multiple pathology labs around the world have already deployed it in routine clinical practice to help improve diagnostic accuracy, Ibex said.

European approval follows results from a blinded, multi-site clinical study at Institut Curie in France and Maccabi Healthcare Services in Israel, with the platform demonstrating high accuracy in detecting various types of breast cancer, including invasive and in-situ cancers. It also distinguished between different types of cancer and grading of DCI…

Read more
  • 0